Logo image
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases
Journal article   Open access   Peer reviewed

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases

Peter T. W. Cheng, Robert F. Kaltenbach, Hao Zhang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Steven J. Walker, Yan Shi, Ying Wang, …
Journal of medicinal chemistry, v 64(21), pp 15549-15581
11 Nov 2021
PMID: 34709814
url
https://doi.org/10.7270/q2pz5dp9View
Open

Abstract

Chemistry, Medicinal Life Sciences & Biomedicine Pharmacology & Pharmacy Science & Technology
The oxycyclohexyl acid BMS-986278 (33) is a potent lysophosphatidic acid receptor 1 (LPA1) antagonist, with a human LPA1 Kb of 6.9 nM. The structure-activity relationship (SAR) studies starting from the LPA1 antagonist clinical compound BMS-986020 (1), which culminated in the discovery of 33, are discussed. The detailed in vitro and in vivo preclinical pharmacology profiles of 33, as well as its pharmacokinetics/metabolism profile, are described. On the basis of its in vivo efficacy in rodent chronic lung fibrosis models and excellent overall ADME (absorption, distribution, metabolism, excretion) properties in multiple preclinical species, 33 was advanced into clinical trials, including an ongoing Phase 2 clinical trial in patients with lung fibrosis (NCT04308681).

Metrics

38 Record Views
37 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
International collaboration
Web of Science research areas
Chemistry, Medicinal
Logo image